-
Product Insights
CWP and GE Hybrid Solar PV Park, Albania
CWP and GE Hybrid Solar PV Park is proposed to be built in Kukes, Albania. The project is at the permitting stage. Empower your strategies with our CWP and GE Hybrid Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or...
-
Product Insights
Gastroesophageal (GE) Junction Carcinomas – Drugs In Development, 2023
Global Markets Direct’s, ‘Gastroesophageal (GE) Junction Carcinomas - Drugs In Development, 2023’, provides an overview of the Gastroesophageal (GE) Junction Carcinomas pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastroesophageal (GE) Junction Carcinomas, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tislelizumab in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tislelizumab in Gastroesophageal (GE) Junction Carcinomas Drug Details: Tislelizumab (Baizean, Tevimbra) is a humanized monoclonal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bemarituzumab in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bemarituzumab in Gastroesophageal (GE) Junction Carcinomas Drug Details: Bemarituzumab [FPA-144] is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Gastroesophageal (GE) Junction Carcinomas Drug Details: Durvalumab (MEDI-4736, Imfinzi, Fidursi, Imfinzio) a programmed...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Atezolizumab in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Atezolizumab in Gastroesophageal (GE) Junction Carcinomas Drug Details: Atezolizumab (Tecentriq) is an antineoplastic agent. It...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tremelimumab in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tremelimumab in Gastroesophageal (GE) Junction Carcinomas Drug Details: Tremelimumab (Imjudo) is a human monoclonal monospecific...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amivantamab in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Amivantamab in Gastroesophageal (GE) Junction Carcinomas Drug Details: Amivantamab-vmjw (Rybrevant) is a low-fucose human immunoglobulin...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tiragolumab in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tiragolumab in Gastroesophageal (GE) Junction Carcinomas Drug Details: Tiragolumab (RG-6058, MTIG-7192A, anti-TIGIT) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cabometyx in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cabometyx in Gastroesophageal (GE) Junction Carcinomas Drug Details: Cabozantinib s-malate (Cabometyx, Aptimetyx) is a s-malate...